

1 **Healthy adults possess cross-reactive neuraminidase inhibition antibodies to an A(H5N1)**
2 **clade 2.3.4.4b avian influenza virus A/Black Faced Spoonbill/Hong Kong/AFCD-HKU-22-**
3 **21429-01012/2022**

4

5 **Authors:** Pavithra Daulagala, Samuel M. S. Cheng, Alex W. H. Chin, Leo L. H. Luk, Kathy Leung,
6 Joseph T. Wu, Leo L. M. Poon, Malik Peiris¹ and Hui-Ling Yen¹

7 ¹ These senior authors contributed equally to this article.

8

9 **Affiliation:** The University of Hong Kong, Hong Kong SAR, China (P. Daulagala, S. M. S. Cheng,
10 A.W.H. Chin, L.L.H. Luk, K. Leung, J. T. Wu, L.L.M. Poon, M. Peiris, H.-L. Yen); The University
11 of Hong Kong – Shenzhen Hospital, Shenzhen, China (K. Leung); and Hong Kong Science Park,
12 Hong Kong SAR, China (L.L.M. Poon, M. Peiris).

13

14 **Running Title:** Population immunity to clade 2.3.4.4b H5N1 virus

15 **Keywords:** highly pathogenic avian influenza virus, A(H5N1), hemagglutination inhibition
16 antibody, neuraminidase inhibition antibody, population immunity, pandemic risk assessment

17

18 **Correspondence:** Hui-Ling Yen (hyen@hku.hk) and Malik Peiris (malik@hku.hk)

19 Address – School of Public Health, LKS Faculty of Medicine, 7 Sassoon Rd., Pok Fu Lam, Hong
20 Kong SAR, China.

21

22 The authors report no conflict of interest related to this article.

23

24 Title: 169 characters with spaces, Abstract: 50 words; Text: 1012 words; Figures: 2; Tables: 2;
25 References: 15

26 **Abstract**

27 Hemagglutination inhibition (HI) and neuraminidase inhibition (NI) antibodies to a clade
28 2.3.4.4b A(H5N1) highly pathogenic avian influenza virus were measured in 63 age-stratified
29 healthy adults in Hong Kong. No HI antibody was detected; 61 subjects had detectable NI
30 antibodies to A(H5N1). NI titers to A(H5N1) and A(H1N1)pdm09 viruses were correlated.

31

32 **Text**

33 The A/Goose/Guangdong/1/1996-like (GsGd-like) A(H5N1) highly pathogenic avian
34 influenza viruses were first identified in 1996 and have continuously evolved into distinct HA
35 clades that are antigenically different. Prior to 2005, the GsGd-like virus mainly circulated in Asia
36 among domestic poultry (including land-based poultry and domestic waterfowls). Spill-over
37 infections from domestic poultry to wild migratory birds have facilitated long-distance spread into
38 different continents (1, 2). In 2005, the clade 2.2 viruses spread from China to Europe, the Middle
39 East, and Africa. In 2014-2015, the clade 2.3.4.4c viruses with new NA proteins acquired through
40 genetic reassortment spread from Asia to Europe and North America. Since 2016, the clade
41 2.3.4.4b viruses have continued to cause outbreaks in domestic poultry in Europe (3) and become
42 enzootic among wild birds in 2021 (4), and further spread to North America and South America in
43 2021-2022. With expanded genetic diversity and geographic distribution, spill-over events into
44 numerous mammalian species and sporadic human infections were also documented (5). While
45 the HPAI (H5N1) virus has not yet achieved efficient transmissibility in humans, the current
46 epidemiology of A(H5N1) 2.3.4.4b lineage raises pandemic concern.

47 Population immunity to an emerging influenza virus is one of the key parameters
48 considered while assessing its pandemic risk (6, 7). Neutralizing antibodies targeting the receptor

49 binding domain of HA and antibodies that inhibit NA activity have been shown to correlate with
50 protection against influenza infection (8, 9). Here, we aimed to evaluate if the general population
51 possess cross-reactive antibody responses to the A(H5N1) through prior exposures to seasonal
52 influenza viruses. Sera from healthy blood donors (N=63) aged 18-73 years (born between 1947-
53 2002) collected from April 2020 – August 2020 in Hong Kong (HKU/HA HKW Institutional
54 Review Board approval #UW-132) were used to determine cross-reactive HI antibodies and NI
55 antibodies against a HPAI (H5N1) clade 2.3.4.4b virus A/Black Faced Spoonbill/Hong
56 Kong/AFCD-HKU-22-21429-01012/2022 (Spoonbill/HK/22) isolated in November 2022. The
57 HA protein of Spoonbill/HK/22 (GISAID: EPI2581007) shared 98.8% and 98.6% homology to
58 the HA proteins of candidate vaccine viruses (CVVs) of clade 2.3.4.4b; A/chicken/Ghana/AVL-
59 76321VIR7050-39/2021 and A/American wigeon/South Carolina/AH0195145/2021, respectively.
60 Similarly, the NA protein of Spoonbill/HK/22 (GISAID: EPI2581009) shared a homology of
61 97.3% and 97.2% with the NA proteins of CVVs; A/chicken/Ghana/AVL-76321VIR7050-39/2021
62 and A/American wigeon/South Carolina/AH0195145/2021, respectively (10). As H5 and H1
63 belong to Group 1 HA, we also determined the HI and NI antibody responses towards
64 A/California/04/2009 (California/09) A(H1N1)pdm09 virus, as exposure to A(H1N1)pdm09 may
65 generate cross-reactive HI and NI antibodies to A(H5N1). HI and NI antibodies were determined
66 using hemagglutination inhibition assay (11) and enzyme-linked lectin assay (12), respectively.

67 Among 63 healthy adults, 53/63 (84.1%) possessed detectable HI antibodies at $\geq 1:10$ to
68 California/09, with the highest HI response observed in the 10-19 years old age group. However,
69 none showed detectable HI antibodies at $\geq 1:10$ to Spoonbill/HK/22 (Figure 1). 57/63 (90.5%)
70 healthy subjects showed detectable NI antibodies at $\geq 1:10$ against California/09, with the highest
71 NI response observed in the 10-19 years old age group. Interestingly, 61/63 (96.8%) healthy

72 subjects possessed cross-reactive NI response at $\geq 1:10$ and 36/63 (57.1%) had NI titres of $\geq 1:40$
73 to Spoonbill/HK/22. The NI titers against California/09 and Spoonbill/HK/22 were highly
74 correlated ($r=0.8349$, Spearman's correlation, $p < 0.001$). Specifically, 57 (90.5%) and 32 (50.8%)
75 subjects had NI antibodies to both viruses at titers $\geq 1:10$ and $\geq 1:40$, respectively.

76 To delineate the potential exposure history in healthy adults that lead to cross-reactive NI
77 response to Spoonbill/HK/22, archival ferret anti-sera raised against A(H1N1) viruses and
78 A(H1N1)pdm09 (California/09) were used to determine NI responses against the homologous
79 virus and Spoonbill/HK/22 (Table 1). Ferret anti-sera raised against A(H1N1) viruses circulated in
80 1977-2007 showed no cross-reactive NI response to Spoonbill/HK/22, despite of detectable NI
81 titers at 1:320 to 1:1280 against the homologous viruses. Ferret anti-sera raised against
82 California/09 showed a homologous NI titer of 1:2560 and cross-reactive NI titres to
83 Spoonbill/HK/22 at 1:320 to 1:640. The NA proteins of Spoonbill/HK/22 and California/09
84 differed by 53 amino acids (88.1% homology), while the NA proteins of Spoonbill/HK/22 and
85 seasonal A(H1N1) viruses differed by 68 – 76 amino acids (84.1% to 84.6% homology) (Table 2).
86 More amino acid substitutions were observed in the NA head domain of A/Brisbane/59/2007
87 (Brisbane/07) ($n=54$ amino acid differences) than California/09 H1N1 viruses ($n=34$ amino acid
88 differences), in comparison to Spoonbill/HK/22 (Figure 2 and Table 2).

89

90 **Conclusion**

91 We detected cross-reactive NI antibodies among healthy adults against a clade 2.3.4.4b
92 A(H5N1) virus, Spoonbill/HK/22, a virus genetically closely related to A(H5N1) viruses recently
93 circulating in Europe and the Americas. The NI response to A(H5N1) was highly correlated with
94 the NI response to the A(H1N1)pdm09 virus. Our results confirm and extend the findings from a

95 recent study on detecting cross-reactive NI antibody responses to clade 2.3.4.4b A(H5N1) virus in
96 healthy blood donors (13). Using archival ferret anti-sera raised against seasonal A(H1N1) and
97 A(H1N1)pdm09 influenza viruses, cross-reactive NI response to A(H5N1) was only detected in
98 ferret sera infected with A(H1N1)pdm09, but not seasonal A(H1N1) viruses circulated in 1977-
99 2007. The A(H1N1)pdm09 virus derived its NA protein from the avian-origin Eurasian-avian
100 swine viruses (14) and appeared antigenically more closely related to the N1 of recent clade
101 2.3.4.4b H5N1 viruses and may thus provide partial protection against H5N1 HPAIV infection.
102 Anti-NA antibodies have been identified to correlate with protection, specifically to protect against
103 infection, reduce symptoms, and shorten the duration of viral shedding (9). HI titer of $\geq 1:40$ has
104 long been established as a surrogate for protection against influenza virus infections, allowing for
105 estimating the impact of cross-reactive HI antibody titers in age-stratified human sera on reducing
106 the reproduction number R_0 of a novel zoonotic virus that may acquire transmissibility in humans
107 (15). However, levels of NI antibodies that correlate with protection have not been clearly defined
108 and it is therefore not possible to assess the impact of the observed cross-reactive NI antibody to
109 A(H5N1) at the population level.

110 Taken together, high titers of cross-reactive NI antibodies against NA of HPAI (H5N1)
111 clade 2.3.4.4b viruses are detected in human sera, although there are no cross-reactive HI
112 antibodies. This suggests that NI antibodies generated against conserved epitopes across human
113 and avian N1 NA may partially protect humans against A(H5N1) infection or modulate disease
114 severity.

115

116 **Biographical sketch:** Dr. Daulagala is a researcher at the School of Public Health, University of
117 Hong Kong. Her research interest is to understand the role of anti-NA antibodies against influenza
118 infections.

119

120 **Acknowledgements**

121 The authors thank Dr. Christopher J. Brackman from the Agriculture Fisheries and Conservation
122 Department (AFCD), Government of the Hong Kong Special Administrative Region (SAR),
123 China, for sharing the A(H5N1) virus. This study was supported by RGC Theme-based Research
124 Schemes (T11-712/19-N), Hong Kong SAR, China.

125

126 **References**

- 127 1. Caliendo V, Lewis NS, Pohlmann A, Baillie SR, Banyard AC, Beer M, et al. Transatlantic
128 spread of highly pathogenic avian influenza H5N1 by wild birds from Europe to North
129 America in 2021. *Sci Rep.* 2022;12(1):11729. Epub 20220711. doi: 10.1038/s41598-022-
130 13447-z. PubMed PMID: 35821511; PubMed Central PMCID: PMC9276711.
- 131 2. Verhagen JH, Fouchier RAM, Lewis N. Highly Pathogenic Avian Influenza Viruses at the
132 Wild-Domestic Bird Interface in Europe: Future Directions for Research and Surveillance.
133 *Viruses.* 2021;13(2). Epub 20210130. doi: 10.3390/v13020212. PubMed PMID: 33573231;
134 PubMed Central PMCID: PMC7912471.
- 135 3. European Food Safety Authority ECfDP, Control EURLfAI, Adlhoch C, Fusaro A, Gonzales
136 JL, Kuiken T, et al. Avian influenza overview September - December 2022. *EFSA J.*
137 2023;21(1):e07786. Epub 20230119. doi: 10.2903/j.efsa.2023.7786. PubMed PMID:
138 36698491; PubMed Central PMCID: PMC9851911.
- 139 4. Pohlmann A, King J, Fusaro A, Zecchin B, Banyard AC, Brown IH, et al. Has Epizootic
140 Become enzootic? Evidence for a fundamental change in the infection dynamics of highly
141 pathogenic avian influenza in Europe, 2021. *mBio.* 2022;13(4):e0060922. Epub 20220621.
142 doi: 10.1128/mbio.00609-22. PubMed PMID: 35726917; PubMed Central PMCID:
143 PMC9426456.
- 144 5. WHO. Antigenic and genetic characteristics of zoonotic influenza A viruses and development
145 of candidate vaccine viruses for pandemic preparedness: Geneva: World Health Organization.;
146 2022. Available from: <https://cdn.who.int/media/docs/default-source/influenza/who->

- 147 [influenza-recommendations/vcmmnorthern-hemisphere-recommendation-2022-](https://www.who.int/influenza-recommendations/vcmmnorthern-hemisphere-recommendation-2022-2023/202203_zoonotic_vaccinevirusupdate.pdf)
148 [2023/202203_zoonotic_vaccinevirusupdate.pdf](https://www.who.int/influenza-recommendations/vcmmnorthern-hemisphere-recommendation-2022-2023/202203_zoonotic_vaccinevirusupdate.pdf).
- 149 6. Cox NJ, Trock SC, Burke SA. Pandemic preparedness and the Influenza Risk Assessment
150 Tool (IRAT). *Curr Top Microbiol Immunol*. 2014;385:119-36. doi: 10.1007/82_2014_419.
151 PubMed PMID: 25085014.
- 152 7. WHO. Tool for Influenza Pandemic Risk Assessment (TIPRA). 2 ed: Geneva: World Health
153 Organization.; 2020.
- 154 8. Krammer F, Weir JP, Engelhardt O, Katz JM, Cox RJ. Meeting report and review:
155 Immunological assays and correlates of protection for next-generation influenza vaccines.
156 *Influenza and Other Respiratory Viruses*. 2020;14(2):237-43. doi:
157 <https://doi.org/10.1111/irv.12706>.
- 158 9. Maier HE, Nachbagauer R, Kuan G, Ng S, Lopez R, Sanchez N, et al. Pre-existing
159 Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza
160 A(H1N1)pdm Virus Shedding and Illness in Naturally Infected Adults. *Clin Infect Dis*.
161 2020;70(11):2290-7. doi: 10.1093/cid/ciz639. PubMed PMID: 31300819; PubMed Central
162 PMCID: PMC7245146.
- 163 10. WHO. Summary of status of development and availability of A(H5N1) candidate vaccine
164 viruses and potency testing reagents Geneva: World Health Organization2023. Available from:
165 [https://cdn.who.int/media/docs/default-source/influenza/cvvs/cvv-zoonotic-northern-](https://cdn.who.int/media/docs/default-source/influenza/cvvs/cvv-zoonotic-northern-hemisphere-2023-2024/h5n1_summary_a_h5n1_cvv_20230225.pdf?sfvrsn=cccc2a09_3&download=true)
166 [hemisphere-2023-](https://cdn.who.int/media/docs/default-source/influenza/cvvs/cvv-zoonotic-northern-hemisphere-2023-2024/h5n1_summary_a_h5n1_cvv_20230225.pdf?sfvrsn=cccc2a09_3&download=true)
167 [2024/h5n1_summary_a_h5n1_cvv_20230225.pdf?sfvrsn=cccc2a09_3&download=true](https://cdn.who.int/media/docs/default-source/influenza/cvvs/cvv-zoonotic-northern-hemisphere-2023-2024/h5n1_summary_a_h5n1_cvv_20230225.pdf?sfvrsn=cccc2a09_3&download=true).
- 168 11. WHO. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva:
169 World Health Organization; 2011.
- 170 12. Couzens L, Gao J, Westgeest K, Sandbulte M, Lugovtsev V, Fouchier R, et al. An optimized
171 enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody
172 titers in human sera. *J Virol Methods*. 2014;210:7-14. Epub 20140916. doi:
173 10.1016/j.jviromet.2014.09.003. PubMed PMID: 25233882.
- 174 13. Kandeil A, Patton C, Jones JC, Jeevan T, Harrington WN, Trifkovic S, et al. Rapid evolution
175 of A(H5N1) influenza viruses after intercontinental spread to North America. *Nat Commun*.
176 2023;14(1):3082. Epub 20230529. doi: 10.1038/s41467-023-38415-7. PubMed PMID:
177 37248261; PubMed Central PMCID: PMC10227026.
- 178 14. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic
179 characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.
180 *Science*. 2009;325(5937):197-201. Epub 20090522. doi: 10.1126/science.1176225. PubMed
181 PMID: 19465683; PubMed Central PMCID: PMC3250984.
- 182 15. Cheung JTL, Tsang TK, Yen HL, Perera R, Mok CKP, Lin YP, et al. Determining Existing
183 Human Population Immunity as Part of Assessing Influenza Pandemic Risk. *Emerg Infect Dis*.
184 2022;28(5):977-85. doi: 10.3201/eid2805.211965. PubMed PMID: 35447069; PubMed
185 Central PMCID: PMC9045452.

186

187

188

189

190 **Tables**

191

192 **Table 1. NI antibody response in post-infection ferret anti-sera against NA of**
 193 **Spoonbill/HK/22 and California/09**

Post-infection ferret anti-sera	NI antibody titer measured using A(H6N1) viruses		
	Homologous virus A(H1N1)	California/09 A(H1N1)	Spoonbill/HK/22 A(H5N1)
A/USSR/90/1977	320	<10	<10
A/Chile/01/1983	320	<10	<10
A/Singapore/06/1986	320	<10	<10
A/Texas/36/1991	320	<10	<10
A/Brisbane/59/2007	1280	<10	<10
A/California/04/2009_pdm09	2560	2560	320-640*

211 *NI titer range detected in n=6 ferret anti-sera

212

213

214 **Table 2. Number of amino acid differences in the NA proteins of A(H1N1) and**
215 **A(H1N1)pdm09 viruses in comparison to A(H5N1)**

A(H1N1) strain	Amino acid differences compared to Spoonbill/HK/22	Homology (%)
A/USSR/90/1977	70	84.08
A/Chile/01/1983	68	84.58
A/Singapore/06/1986	68	84.58
A/Texas/36/1991	69	84.33
A/Brisbane/59/2007	76	83.83
A/California/04/2009_pdm09	53	88.00

226

227

228

229 **Figure Legends**

230 **Figure 1. HI and NI antibody responses against California/09 and H5N1 with age in healthy**

231 **adults.** A scatter graph with a bar showing the HI and NI antibody response measured against

232 California/09 (H1N1) and Spoonbill/HK/22 (H5N1) in different age groups with an x-axis

233 showing the age group and y-axis showing the HI and NI titers measured. The sample size of each

234 age group is shown within the brackets (n=x). The HI and NI titers measured against California/09

235 are shown in purple, and the HI and NI titers measured against Spoonbill/HK/22 are shown in

236 green. Each dot in an age group represents a HI or NI titer measured for an individual. The bar

237 generated for the age group represents the mean with standard deviation shown in the black line.

238 Individuals showing HI and NI titer below the detection limit is shown as <1:10. The HI and NI

239 titers across different age groups for each virus was compared using Kruskal Wallis test and

240 Dunn's multiple comparison test. The *p<0.033, **p<0.002, ***p<0.001.

241



242 **Figure 2. Amino acid substitutions on NA proteins of California/09 and Brisbane/07 in**

243 **comparison to the NA of 2.3.4.4b A(H5N1) virus, Spoonbill/HK/22.** The positions of the amino


244 acid differences in the head region of NA are shown on the NA tetrameric structure of

245 A/Vietnam/1203/2004 (PDB 2HU0) generated using the software PyMOL. The NA monomers are

246 indicated in green and the amino acid substitutions are labelled in purple.



NA of California/09



NA of Brisbane/07

